StockNews.com initiated coverage on shares of iBio (NYSE:IBIO – Free Report) in a research note issued to investors on Friday morning. The firm issued a sell rating on the stock.
iBio Trading Down 5.0 %
Shares of IBIO opened at $1.92 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a 1-year low of $1.02 and a 1-year high of $28.20.
iBio (NYSE:IBIO – Get Free Report) last announced its earnings results on Friday, February 9th. The company reported ($2.42) earnings per share for the quarter.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
See Also
- Five stocks we like better than iBio
- Which Wall Street Analysts are the Most Accurate?
- The Charles Schwab Company Can Hit New Highs
- Options Trading – Understanding Strike Price
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
